{"nctId":"NCT03014635","briefTitle":"Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines","startDateStruct":{"date":"2016-12-05","type":"ACTUAL"},"conditions":["Glabellar Frown Lines"],"count":306,"armGroups":[{"label":"DaxibotulinumtoxinA 40 units","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxins, Type A"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebos"]}],"interventions":[{"name":"Botulinum Toxins, Type A","otherNames":["DaxibotulinumtoxinA"]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide written informed consent including authorization to release health information\n* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS) scale\n* Moderate (2) or severe (3) glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity (PFWS) scale\n* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial\n\nExclusion Criteria:\n\n* Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A, including peripheral motor neuropathic diseases such as amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis\n* Active skin disease, infections or inflammation at the injection sites\n* Plan to receive botulinum toxin type A anywhere in the face through the duration of the study\n* History of allergy or sensitivity to any botulinum toxin preparations or to any component of the test article\n* Current enrollment in an investigational drug or device trial or participation in such a trial within the last 30 days prior to screening through end of trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Achieved â‰¥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales","description":"Percentage of subjects who achieve at least a 2-point improvement from baseline and a score of 0 or 1 (i.e., none or mild wrinkles in severity) on both Investigator and Subject Frown Wrinkle Severity (FWS) assessments","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Time to Return to Moderate to Severe on Both IGA-FWS and PFWS Scales for DaxibotulinumtoxinA for Injection Group","description":"The duration of response will be evaluated by analyzing the number of days to return to moderate or severe on both IGA-FWS and PFWS scales for DaxibotulinumtoxinA for Injection group.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"The Time to Return to, or Worse Than, Baseline on Both IGA-FWS and PFWS Scales for DaxibotulinumtoxinA for Injection Group","description":"The duration of response will be evaluated by analyzing the number of days to return to, or worse than, baseline on both IGA-FWS and PFWS scales for DaxibotulinumtoxinA for Injection group.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":205},"commonTop":["Headache","Nasopharyngitis"]}}}